Sofia Gameiro, Ph.D.
Dr. Gameiro is a Staff Scientist and Head of the Immunomodulation Group in the Laboratory of Tumor Immunology and Biology, NCI. She received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo, NY. Dr. Gameiro's research interests include immune modulation; tumor microenvironment; tumor immunology. The Immunomodulation Group examines how emerging therapeutics can modulate the immune system to exert potent antitumor activity, with particular emphasis on how the mechanisms involved can be exploited to maximize antitumor activity in combination regimens with novel immunotherapies and other anticancer modalities. These studies form the rationale for novel hypothesis-driven clinical interventions.
Center for Cancer Research
National Cancer Institute
Building 10, Room 5B46
Bethesda, MD 20892
As of June 11, 2018: 240-858-3439
Our research program is focused on identifying and exploiting immune mechanisms elicited by novel immunotherapeutics and emerging anticancer agents with the goal of maximizing antitumor efficacy in combination regimens. We are examining the mechanisms through which anticancer agents can reprogram the immunosuppressive tumor microenvironment to allow for efficient immunological control of tumor growth. We hypothesize that effective cancer control and long-term survival benefit can be attained by strengthening the patient’s own immune system through the combination of multiple immune modulating agents.
Selected Key Publications
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.OncoImmunology. 7: e1426519, 2018. [ Journal Article ]
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.Oncotarget. 7: 7390-402, 2016. [ Journal Article ]
Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing.Int J Radiat Oncol Biol Phys. 95: 120-30, 2016. [ Journal Article ]
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing .Oncotarget. 5: 403-16, 2014. [ Journal Article ]
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T-lymphocytes and is distinct from immunogenic cell death.Int J Cancer. 133: 624-36, 2013. [ Journal Article ]
Dr. Sofia Gameiro received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo in 2008. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2017. Dr. Gameiro’s current research focuses on identifying and exploiting mechanisms through which anticancer agents can reprogram the immunosuppressive tumor microenvironment to allow for efficient immune-mediated elimination of cancer cells.
|Kristin C. Hicks Ph.D.||Postdoctoral Fellow (CRTA)|
|Karin M. Knudson Ph.D.||Postdoctoral Fellow (CRTA)|
|Curtis Randolph||Laboratory Technician (Contr)|